Petrelintide Shows Weight Loss, but GLP-1 Test Awaits

Roche’s experimental obesity drug petrelintide produced mean weight loss of up to 10.7% after 42 weeks in a Phase II trial. For someone who has struggled with stomach side effects on an obesity medicine, another appetite pathway sounds appealing. The trial put petrelintide up against a placebo, though, rather than a GLP-1 medicine. It leaves the question of whether switching treatments would make nausea easier to live with.

In March, Roche announced the ZUPREME-1 results: the petrelintide group with the greatest weight reduction lost a mean 10.7% of starting body weight at week 42, compared with 1.7% in the placebo group. All five tested doses met the trial’s primary weight-loss endpoint at week 28, the company said. The research was subsequently presented at the European Association for the Study of Diabetes meeting and published in The Lancet Diabetes & Endocrinology. Its comparison arm remained placebo.

A Different Route to Feeling Full

Petrelintide is designed to mimic amylin, a hormone released by the pancreas that helps regulate appetite through mechanisms partly separate from those targeted by incretin drugs. That gives researchers a reason to test it for people who have trouble tolerating other appetite medicines. The stomach still gets a vote: a different hormone target alone cannot predict how someone will feel while a dose increases.

ZUPREME-1 was a randomized, double-blind, placebo-controlled dose-finding study. Roche describes 493 participants with obesity or overweight and weight-related conditions. The account of the published research specifies 485 people who were randomized and received injections. Those figures are not reconciled in the accounts. Participants received weekly petrelintide or placebo alongside dietary guidance and physical-activity recommendations. The reported weight loss belongs to that full study routine, including lifestyle counseling.

The trial tested a dosing timetable as well as a drug. Doses increased every fourth week for up to 16 weeks before the maintenance period continued to week 42. The 10.7% figure is the mean in the best-performing dose group under that schedule. It does not describe all five doses or predict any one person’s result. A patient considering weekly injections would spend months getting to a maintenance dose; the experience during those months belongs beside the week-42 number.

The Stomach Question Starts Before Maintenance

Roche reported that 4.8% of participants in the maximally effective petrelintide arm stopped treatment because of adverse events, compared with 4.9% on placebo. Most reported gastrointestinal adverse events were mild, the company said, and it reported no vomiting in that petrelintide arm. Those figures give the drug a promising case for further testing. With no semaglutide or tirzepatide arm, they cannot establish whether petrelintide would cause fewer stomach problems than either medicine. Someone can also experience nausea and keep taking a drug, so discontinuation alone cannot capture the whole experience.

The account of the petrelintide research cites a semaglutide cardiovascular-outcomes trial in which about 37% of discontinuations were attributed to gastrointestinal side effects. That percentage describes people who discontinued in that trial, not everyone who took semaglutide. Putting it next to ZUPREME-1’s 4.8% would mix denominators, study populations and follow-up periods. It would turn two answers to different questions into an apparent head-to-head result.

Petrelintide’s earlier trial makes the dose schedule especially interesting. Roche says nausea was less common in ZUPREME-1 than in a prior 16-week Phase 1b trial, which increased doses every second week rather than every fourth. Waiting longer between increases could have contributed. Because other features of the trials differed, the change cannot be assigned to those extra two weeks alone. Roche also said almost no nausea events were reported after participants reached their maintenance dose. For someone making a treatment decision, nausea during escalation may carry more weight than a reassuring account of maintenance.

ZUPREME-1’s design included follow-up through week 51. Roche’s March topline release did not report results from that post-treatment period; it said final data, including a nine-week safety follow-up, would be presented later. The week-42 weight result describes the studied treatment schedule, not years of weight maintenance. Trial authors including Timothy Garvey have proposed amylin treatment as a possible long-term option if the findings hold up in confirmatory Phase III trials. For now, that is a case to test rather than a demonstrated replacement for an existing medicine.

One Appetite Pathway, or Two?

ZUPREME-1 tested petrelintide without an incretin drug. A separate Phase 2b study of EloraTZP tested eloralintide, another amylin-receptor drug, together with tirzepatide, which acts on GIP and GLP-1 receptors. Its 367 participants had overweight or obesity and type 2 diabetes. At 48 weeks, the highest-dose combination group had mean weight loss of 23.3% and a reported decrease in HbA1c, a measure of blood-sugar control.

That combination required two separate pen injections. Gastrointestinal events occurred more frequently in its combination arms than with eloralintide or tirzepatide alone, according to the meeting findings. The 23.3% and 10.7% results cannot rank EloraTZP against petrelintide: the studies tested different drugs in different populations, with different comparison arms and follow-up times. They do put a practical choice on the table for future research. If an amylin drug can be used alone or alongside an incretin drug, researchers will need to measure what the second treatment adds to weight and blood-sugar outcomes, and what it adds to the burden of taking it.

Weight is one measurement of that burden and benefit. In a separate Phase II semaglutide study, investigators added trevogrumab, an antibody that blocks myostatin, to study preservation of lean mass during weight loss. They measured body weight, fat mass and lean mass, with an imaging substudy examining muscle volume. ZUPREME-1 also included MRI-measured body composition as an exploratory endpoint, but Roche’s March topline release gave no result for it. The semaglutide study tested another drug and another question; it shows the sort of information a scale percentage leaves out, without supplying a body-composition verdict on petrelintide.

Petrelintide’s best-performing arm gives researchers a reason to keep going: double-digit mean weight loss and few participants stopping because of adverse events. A future comparison with an active treatment could ask the question a placebo arm cannot: during dose increases, who can keep taking the medicine, and what weight change comes with that choice?